EyeSol® Technology

Novaliq’s innovative EyeSol® drug delivery technology is based on novel and exclusive water-free excipients which have been established and validated as key ingredients for innovative ophthalmic products:

  • the technology platform is disruptive and IP protected;
  • the pipeline is rich with first-in-class candidates for dry eye, glaucoma and retinal diseases;
  • the technology is clinically proven to be safe and effective;
  • Novaliq has generated a broad range of clinical and pre-clinical data to confirm safety, tolerability, efficacy and comfort.

How does the EyeSol® drug delivery technology work?

Our EyeSol® technology enhances traditionally water-insoluble or unstable drugs resulting in:

  • eye drops with better and higher solubility, stability, bioavailability, safety and comfort;
  • overcoming the limitations of water-based drug instabilities;
  • formulations that are always water-free and therefore preservative-free;
  • better penetration in tissues;
  • better drug delivery, efficacy and longer retention;
  • multi-dose presentations;
  • small drop size, excellent spreading.

Our fast and proven drug development process increases success and time to market.

What are the benefits of the technology?

Novaliq’s disruptive, IP protected EyeSol® technology platform enables our partners to

  • get access to innovative products to protect, treat and manage ocular diseases for increased effectiveness and better stability;
  • formulate and stabilize a wide range of APIs, including macromolecules and proteins;
  • enable poorly soluble APIs by utilizing a new kind of drug delivery.